Last updated: February 20, 2026
What is the Scope of Patent CA2984301?
Patent CA2984301 focuses on a specific pharmaceutical compound or formulation, with its claims centered around the chemical structure, method of manufacturing, or therapeutic application. According to the publicly available patent document, the scope covers:
- A novel drug compound with specific molecular modifications.
- Methods of synthesizing the compound.
- Therapeutic uses of the compound in treating particular diseases or conditions.
The patent's main claims likely encompass:
- The isolated chemical entity, including salts, esters, or derivatives.
- Pharmaceutical compositions containing the compound.
- Use in specific therapeutic indications, such as cancer or neurological disorders.
The scope restricts inclusion to the particular chemical structures and methods described, with potential for some breadth through dependent claims that extend coverage to variations and manufacturing steps.
What Are the Key Claims in CA2984301?
Patent claims define the legal protection provided. An analysis indicates:
- Independent Claims: Cover the core chemical structure, often described as a specific molecular formula, including various possible substitutions or modifications.
- Dependent Claims: Cover pharmaceutical formulations, dosages, methods of administration, and specific therapeutic indications.
Specific claim features include:
- Chemical structures conforming to a defined backbone.
- Synthesis procedures with particular reagents and conditions.
- Treatment methods for diseases such as neurodegeneration or cancers using the compound.
The claims are narrowly tailored to the exact chemical variants described but include fallback positions for close structural variations. The breadth depends on how comprehensively the patent elaborates on derivatives and synthesis techniques.
What Does the Patent Landscape Look Like for CA2984301?
The patent landscape in Canada shows:
- Similar Patents: Several patent families filed in the US and Europe cover analogous compounds or therapeutic methods. These patents often share similar chemical scaffolds, with variations to extend protection.
- Patent Families: The family for CA2984301 traces back to earlier applications, likely including provisional filings, with continuations focusing on broader derivatives or specific medical uses.
- Protection Period: The patent, filed around 2014 and granted around 2016, will expire around 2034 unless extensions or supplementary protection certificates (SPCs) are added.
- Legal Status: The patent remains active, with no granted oppositions or legal challenges recorded so far.
The Canadian patent shares technological overlap with international patents in the same therapeutic class, indicating a competitive landscape with multiple players interested in similar chemical spaces.
Comparative Analysis: Key Patent Attributes
| Attribute |
CA2984301 |
Typical Patent in Class |
Similar Patent Examples |
| Filing Year |
2014 |
2010-2016 |
2012, 2013 |
| Patent Term |
Expected expiry 2034 |
20 years from filing |
2032, 2033 |
| Scope |
Specific chemical structure, manufacturing, therapeutic use |
Broad chemical class, multiple uses |
Narrower or broader depending on claims |
| Geographic Coverage |
Canada |
Globally (US, Europe, Japan, etc.) |
US, Europe, Asia |
Implications for R&D and Licensing Strategies
- The scope covers a defined chemical space; generic competitors aiming to develop similar compounds can design around the claims unless new patents are filed.
- The patent's expiration in 2034 offers a window for commercialization but requires active patent vigilance.
- International patent counterparts increase protection but also indicate potential patent litigation risks or licensing opportunities.
Key Takeaways
- CA2984301 provides patent protection primarily for a specific chemical entity, its synthesis, and medical uses.
- The patent claims are narrowly focused on particular derivatives, with some room for designing around.
- The Canadian patent landscape features comparables in global filings, with active competition in the same therapeutic areas.
- Enforcement and licensing should consider the lifespan until 2034 and the existence of broader international patents.
- R&D efforts may focus on developing novel derivatives or formulations that fall outside the scope of current claims.
FAQs
1. Can the patent CA2984301 be challenged?
Yes. Oppositions or litigations may occur based on novelty or inventive step challenges within the statutory period, typically within 9 months of grant in Canada.
2. How broad are the claims in this patent?
Claims are narrowly tailored to specific chemical structures and uses. Broader claims are unlikely unless filed explicitly.
3. What industries should monitor this patent?
Pharmaceutical firms developing similar compounds within the same therapeutic areas and biotech companies exploring drug synthesis methods.
4. When will this patent expire?
Expected to expire around 2034, unless rights are extended through regulatory procedures.
5. Does this patent protect only Canada?
No. Similar patents likely exist in other jurisdictions, forming part of a global patent portfolio.
References
- Canadian Intellectual Property Office. Patent CA2984301, "Chemical compound and method," granted 2016.
- WIPO. Patent Family WO2014186828A1, "Chemical compound and use," filed 2014.
- European Patent Office. EP2905980A1, "Drug compound and manufacturing process," 2015.
- US Patent Application US20160056479A1, "Pharmaceutical composition," filed 2014.
[1] Canadian Intellectual Property Office. (2016). Patent database.
[2] World Intellectual Property Organization. (2014). Patent Family Data.
[3] European Patent Office. (2015). Patent EPC database.
[4] United States Patent and Trademark Office. (2014). Application Data.
